10 min listen
ACCEL Lite: Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis--Focus on AL
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
ACCEL Lite: Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis--Focus on AL
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
ratings:
Length:
12 minutes
Released:
Feb 22, 2022
Format:
Podcast episode
Description
Cardiac amyloidosis is an often overlooked and thus misdiagnosed form of a restrictive cardiomyopathy in which delayed diagnosis is associated with significant morbidity and mortality. Immunoglobulin light chain (AL) cardiac amyloidosis is the most deadly from of cardiac amyloidosis but significant progress has been made in treatment with the first FDA approved therapy for this condition - daratumumab. In this interview, Mathew Maurer, MD and Stephen J. Nicholls, MBBS, PhD, FACC, with Yuvraj Chowdhury, MD, discuss Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis--Focus on AL.
Released:
Feb 22, 2022
Format:
Podcast episode
Titles in the series (100)
ACCEL Lite: ESC Congress 2021 Late Breaker: IAMI: In this interview, Laxmi Mehta, MD, FACC, and Ole Frobert, MD, PhD, and discuss the ESC Congress 2021 late breaker IAMI. This study evaluates whether influenza vaccination improves outcomes in patients with recent MI. Influenza vaccine reduced the... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research